

# Anti-IL-6R $\alpha$ (Sarilumab), Human IgG1 Antibody

rev 02/21

---

**CATALOG NO.:** A2133-100 (100  $\mu$ g)
 

---

**BACKGROUND DESCRIPTION:** The research-grade biosimilar is a fully human anti-IL-6R monoclonal IgG1 antibody that can bind to membrane as well as soluble forms of interleukin 6 receptor (IL-6R). This leads to inhibition of IL-6 mediated signaling and reduced release of CRP, serum amyloid A and fibrinogen, which are potential biomarkers of rheumatoid arthritis (RA). The original monoclonal antibody received US-FDA approval in 2017 to treat moderate to severe RA in combination with methotrexate. The original antibody is currently being evaluated for phase 3 clinical trial on COVID-19 patients

**ALTERNATE NAMES:** IL6Q, gp80, CD126, IL6RA, IL6RQ, IL-6RA, IL-6R-1, HIES5, IL-6R, IL-1Ra, IL6QTL, IL-6R-Alpha, IL6R, IL-6R 1

**ANTIBODY TYPE:** Monoclonal

**HOST/ISOTYPE:** Recombinant / Human IgG1

**SOURCE:** CHO cells

**IMMUNOGEN:** Sarilumab

**MOLECULAR WEIGHT:** 144.13 kDa

**FORM:** Liquid

**FORMULATION:** In PBS buffer, pH 7.2

**STORAGE CONDITIONS:** Undiluted antibody solution should be stored at 4°C in the dark and avoid freezing the solution

**APPLICATIONS AND USAGE:** In vitro and In vivo studies

**This information is only intended as a guide. The optimal dilutions must be determined by the user**

**RELATED PRODUCTS:**

Anti-IL-6 receptor (Tocilizumab), Human IgG1 Antibody (A1447)  
 Anti-PD-1 (Pembrolizumab), Humanized Antibody (A1306)  
 Anti-IL-6 Antibody (A1398)  
 Anti-PD-L1 (Durvalumab), Human IgG1 Antibody (A2109)  
 Anti-IL-2R alpha (CD25) (Basiliximab), Human IgG1 Antibody (A1098)

**FOR RESEARCH USE ONLY! Not to be used on humans.**